These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 30301411

  • 1. An overview about the impact of hinge region towards the anticancer binding affinity of the Ck2 ligands: a quantum chemical analysis.
    Deepa P, Thirumeignanam D, Kolandaivel P.
    J Biomol Struct Dyn; 2019 Sep; 37(15):3859-3876. PubMed ID: 30301411
    [Abstract] [Full Text] [Related]

  • 2. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
    Zhou Y, Zhang N, Tang S, Qi X, Zhao L, Zhong R, Peng Y.
    Molecules; 2017 May 19; 22(5):. PubMed ID: 28534839
    [Abstract] [Full Text] [Related]

  • 3. Rational Design of Coumarin Derivatives as CK2 Inhibitors by Improving the Interaction with the Hinge Region.
    Zhang N, Chen WJ, Zhou Y, Zhao H, Zhong RG.
    Mol Inform; 2016 Jan 19; 35(1):15-8. PubMed ID: 27491649
    [Abstract] [Full Text] [Related]

  • 4. Understanding the impact of anticancer halogenated inhibitors and various functional groups (X = Cl, F, CF3, CH3, NH2, OH, H) of casein kinase 2 (CK2).
    Deepa P, Thirumeignanam D.
    J Biomol Struct Dyn; 2022 Jul 19; 40(11):5036-5052. PubMed ID: 33375908
    [Abstract] [Full Text] [Related]

  • 5. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
    Pardhi T, Vasu K.
    J Biomol Struct Dyn; 2018 Jan 19; 36(1):177-194. PubMed ID: 27960601
    [Abstract] [Full Text] [Related]

  • 6. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y, Zhou L, Zhu X, Dai D, Bao Y, Qiu Y.
    J Biomol Struct Dyn; 2019 Jul 19; 37(10):2703-2715. PubMed ID: 30052133
    [Abstract] [Full Text] [Related]

  • 7. Discovery of novel CK2 leads by cross-docking based virtual screening.
    Sun H, Wu X, Xu X, Jiang Z, Liu Z, You Q.
    Med Chem; 2014 Jul 19; 10(6):628-39. PubMed ID: 24286395
    [Abstract] [Full Text] [Related]

  • 8. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
    Qi X, Zhang N, Zhao L, Hu L, Cortopassi WA, Jacobson MP, Li X, Zhong R.
    Biochem Biophys Res Commun; 2019 Apr 30; 512(2):208-212. PubMed ID: 30878184
    [Abstract] [Full Text] [Related]

  • 9. A novel class of selective CK2 inhibitors targeting its open hinge conformation.
    Dalle Vedove A, Zonta F, Zanforlin E, Demitri N, Ribaudo G, Cazzanelli G, Ongaro A, Sarno S, Zagotto G, Battistutta R, Ruzzene M, Lolli G.
    Eur J Med Chem; 2020 Jun 01; 195():112267. PubMed ID: 32283296
    [Abstract] [Full Text] [Related]

  • 10. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
    Di-wu L, Li LL, Wang WJ, Xie HZ, Yang J, Zhang CH, Huang Q, Zhong L, Feng S, Yang SY.
    J Mol Graph Model; 2012 Jun 01; 36():42-7. PubMed ID: 22516037
    [Abstract] [Full Text] [Related]

  • 11. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
    Battistutta R, Mazzorana M, Sarno S, Kazimierczuk Z, Zanotti G, Pinna LA.
    Chem Biol; 2005 Nov 01; 12(11):1211-9. PubMed ID: 16298300
    [Abstract] [Full Text] [Related]

  • 12. Rising trend on the halogen and non-halogen derivatives (Br, Cl, CF3, F, CH3 and NH2) in ruminal β-d-Xylopyranose - a quantum chemical perspective.
    Deepa P, Thirumeignanam D.
    J Biomol Struct Dyn; 2022 Jan 01; 40(1):449-467. PubMed ID: 32880211
    [Abstract] [Full Text] [Related]

  • 13. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition.
    Battistutta R.
    Cell Mol Life Sci; 2009 Jun 01; 66(11-12):1868-89. PubMed ID: 19387547
    [Abstract] [Full Text] [Related]

  • 14. Understanding the potency of malarial ligand (D44) in plasmodium FKBP35 and modelled halogen atom (Br, Cl, F) functional groups.
    Deepa P, Thirumeignanam D.
    J Mol Graph Model; 2020 Jun 01; 97():107553. PubMed ID: 32035313
    [Abstract] [Full Text] [Related]

  • 15. Molecular dynamics simulations reveal structural insights into inhibitor binding modes and mechanism of casein kinase II inhibitors.
    Ul-Haq Z, Ashraf S, Bkhaitan MM.
    J Biomol Struct Dyn; 2019 Mar 01; 37(5):1120-1135. PubMed ID: 29527958
    [Abstract] [Full Text] [Related]

  • 16. Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.
    Protopopov MV, Ostrynska OV, Starosyla SA, Vodolazhenko MA, Sirko SM, Gorobets NY, Bdzhola V, Desenko SM, Yarmoluk SM.
    Mol Divers; 2018 Nov 01; 22(4):991-998. PubMed ID: 29845490
    [Abstract] [Full Text] [Related]

  • 17. A Note of Caution on the Role of Halogen Bonds for Protein Kinase/Inhibitor Recognition Suggested by High- And Low-Salt CK2α Complex Structures.
    Guerra B, Bischoff N, Bdzhola VG, Yarmoluk SM, Issinger OG, Golub AG, Niefind K.
    ACS Chem Biol; 2015 Jul 17; 10(7):1654-60. PubMed ID: 25961323
    [Abstract] [Full Text] [Related]

  • 18. Low-density crystal packing of human protein kinase CK2 catalytic subunit in complex with resorufin or other ligands: a tool to study the unique hinge-region plasticity of the enzyme without packing bias.
    Klopffleisch K, Issinger OG, Niefind K.
    Acta Crystallogr D Biol Crystallogr; 2012 Aug 17; 68(Pt 8):883-92. PubMed ID: 22868753
    [Abstract] [Full Text] [Related]

  • 19. Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors.
    Hammad S, Bouaziz-Terrachet S, Meghnem R, Meziane D.
    J Mol Model; 2020 May 29; 26(6):160. PubMed ID: 32472293
    [Abstract] [Full Text] [Related]

  • 20. Lead optimization, pharmacophore development and scaffold design of protein kinase CK2 inhibitors as potential COVID-19 therapeutics.
    Yadav S, Ahamad S, Gupta D, Mathur P.
    J Biomol Struct Dyn; 2023 Mar 29; 41(5):1811-1827. PubMed ID: 35014595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.